Observing prescription patterns of Lodient Tab for hypertension
An Observation Study on the Identification of Prescription Patterns of Lodient Tab(Telmisartan/S-amlodipine) and the Changes of Symptoms According to the Treatment Effect of Hypertension for Korean Hypertensive Patients
Hanlim Pharm. Co., Ltd. · NCT06214832
This study looks at how well Lodient Tab helps adults with high blood pressure feel better and manage their symptoms over six months.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 4000 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | Hanlim Pharm. Co., Ltd. (industry) |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06214832 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify prescription patterns of Lodient Tab, a combination of Telmisartan and S-amlodipine, and evaluate the changes in hypertension symptoms, specifically blood pressure levels, in patients who have recently been prescribed this medication. Over a period of six months, the study will monitor the effectiveness of Lodient Tab in managing hypertension symptoms among participants. The study will include adults diagnosed with hypertension who have been prescribed Lodient Tab within the last four months or are scheduled to receive it.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 19 years of age who have been diagnosed with hypertension and recently prescribed Lodient Tab.
Not a fit: Patients who are pregnant, nursing, or deemed inappropriate for participation by the investigator may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into effective prescription practices for managing hypertension, potentially leading to improved patient outcomes.
How similar studies have performed: While this study focuses on observational data, similar studies evaluating prescription patterns for hypertension treatments have shown success in identifying effective management strategies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adults over 19 years of age 2. A person diagnosed with hypertension 3. A person who has been first prescribed Lodient Tab within the past 4 months as of the IRB approval date or is scheduled to be prescribed Lodient Tab 4. A person who voluntarily agreed in writing to this study Exclusion Criteria: 1. Pregnant women or nursing mothers 2. Persons subject to prohibition according to the permission of the Lodient Tab 3. Patients who in the judgement of the investigator, were inappropriate to participate in the study
Where this trial is running
Seoul
- Seoul song clinic — Seoul, Korea, Republic of (RECRUITING)
Study contacts
- Study coordinator: Minseob Song
- Email: song2you@naver.com
- Phone: +820222737282
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hypertension